Nov 23, 2021

Inmedix has discovered and is commercializing a novel class of diagnostics and therapeutics. Their approach focuses on autonomic nervous system (ANS) control of stress responses within the brain. “As early investors in disruptive life science and tech companies, we have seen how cutting-edge technologies like Orion and Sparrow’s can bring significant value to their investors. In Orion’s case delivering truly innovative new treatments to patients by effectively targeting G-Protein Coupled Receptors,” says Howard Lubert. "We are pleased to have the support and confidence of a large network of seasoned life science investors,” said Mark Groper, President and CEO of Orion Biotechnology. “With the completion of this funding round, we are positioned to build on the momentum we have created, advance our multi-asset portfolio, and further leverage our proprietary discovery platform to deliver new precision engineered therapies in collaboration with industry partners.” "The Investor Capital Expo brings together the absolute cream of the crop, growth-stage companies in a grand showcase for the angel investment community each year. The enhanced virtual program creates a seamless experience for our thousand plus attendees to not only hear about the best but really get to know these companies on a more intimate level," said Randy Williams, founder and CEO, Keiretsu Forum. Recordings of the programs can be made available by request. About Keiretsu Forum Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists and corporate/institutional investors. Keiretsu Forum was founded in 2000 by Randy Williams. Keiretsu Forum today is a worldwide network of capital, resources, and deal flow with 50+ chapters on four continents. Keiretsu Forum members invest in high-quality, diverse investment opportunities. To date the 3,000+ Keiretsu members have invested over $900 million in 2,400+ companies. MEDIA CONTACT